Ogino, S., Miyamoto, S., Tenjin, T., Kitajima, R., Ojima, K., Miyake, N., Funamoto, Y., Arai, J., Tsukahara, S., Ito, Y., Tadokoro, M., Anai, K., Tatsunami, S., Kubota, H., Kaneda, Y. and Yamaguchi, N. (2011) Effects of Discontinuation of Long-Term Biperiden Use on Cognitive Function and Quality of Life in Schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 78-83.
http://dx.doi.org/10.1016/j.pnpbp.2010.08.030

has been cited by the following article:

• TITLE: Case Reports: Treatment-Resistant Schizophrenia with Severe Type 2 Diabetes Mellitus Treated with Clozapine

  AUTHORS: Junji Gon, Shinji Sakamoto, Manabu Takaki

  KEYWORDS: Clozapine, Treatment-Resistant Schizophrenia, Type 2 Diabetes Mellitus, Brief Assessment of Cognition in Schizophrenia Japanese Version

  JOURNAL NAME: Open Journal of Psychiatry, Vol.6 No.1, January 11, 2016

  ABSTRACT: Objective: Clozapine is regarded as the most effective drug for treatment of schizophrenia but has complex adverse effects associated with hyperglycemia and diabetes mellitus. Method: We report that clozapine was very effective to treat positive, negative, and cognitive symptoms and well tolerated to a treatment-resistant schizophrenia patient with severe type 2 diabetes mellitus (DM) under cautious blood-sugar monitoring. Results: Clozapine itself and discontinuation of other psychotropic and anticholinergic agents after switching may improve cognitive function and adherence to the treatment regimens for schizophrenia and DM. Conclusion: Clozapine can be administered to treatment-resistant schizophrenia patients even with severe DM with caution.